Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic
kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial
program